Results 81 to 90 of about 4,805 (202)

Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia

Pharmaceuticals
Background: Chronic myeloid leukemia is a hematological malignancy characterized by the abnormal proliferation of leukemic cells. Despite significant progress with tyrosine kinase inhibitors, such as Dasatinib, resistance remains a challenge.
Mariarita Spampinato, Tatiana Zuppelli, Ilaria Dulcamare, Lucia Longhitano, Domenico Sambataro, Annalisa Santisi, Amer M. Alanazi, Ignazio A. Barbagallo, Nunzio Vicario, Rosalba Parenti, Alessandra Romano, Giuseppe Musumeci, Giovanni Li Volti, Giuseppe A. Palumbo, Francesco Di Raimondo, Anna Nicolosi, Sebastiano Giallongo, Vittorio Del Fabro   +17 more
doaj   +1 more source

Selinexor Hyperactivates Akt and Induces Its Nuclear Accumulation [PDF]

, 2020
Selinexor is currently being used in several clinical trials for cancer and has shown anti-cancer effects in combination with other chemotherapies. Clinical trials evaluating the use of selinexor in the treatment of triple negative breast cancer are ...
Lawrence, Erin
core   +1 more source

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

American Journal of Hematology, Volume 101, Issue 4, Page 832-863, April 2026.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong, Emily B. Tomasulo, Stefan K. Barta   +2 more
wiley   +1 more source

Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

Journal of Hematology & Oncology, 2021
Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of 
Marie Maerevoet, Josee M. Zijlstra, George Follows, Rene-Olivier Casasnovas, J. S. P. Vermaat, Nagesh Kalakonda, Andre Goy, Sylvain Choquet, Eric Van Den Neste, Brian Hill, Catherine Thieblemont, Federica Cavallo, Fatima De la Cruz, John Kuruvilla, Nada Hamad, Ulrich Jaeger, Paolo Caimi, Ronit Gurion, Krzysztof Warzocha, Sameer Bakhshi, Juan-Manuel Sancho, Michael Schuster, Miklos Egyed, Fritz Offner, Theodoros P. Vassilakopoulos, Priyanka Samal, Matthew Ku, Xiwen Ma, Kelly Corona, Kamal Chamoun, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Miguel Canales   +33 more
doaj   +1 more source

Once-weekly selinexor, bortezomib, and dexamethasone versus twice-weekly bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label phase 3 trial [PDF]

, 2020
Background Selinexor with dexamethasone has demonstrated activity in patients with heavily pretreated multiple myeloma (MM). In a phase 1b/2 study, the combination of oral selinexor with the proteasome inhibitor (PI) bortezomib, and dexamethasone (SVd ...
Anderson, LD, Arazy, M, Auner, H, Bahlis, NJ, Basu, S, Benjamin, R, Bila, J, Cavo, M, Chai, Y, Delimpasi, S, Dimopoulos,, MA, Dolai, TK, Doronin, V, Facon, T, Galli, M, Garg, M, Gatt, ME, Gavriatopoulou, M, Gironella, M, Grosicki, S, Hajek, R, Jagannath, S, Jeha, J, Joshi, AA, Jurczyszyn, A, Katodritou, E, Kauffman, MG, Korenkova,, S, Kriachok, I, Kumar, J, Leleu, X, Levy, M, Li, L, Liberati, AM, Mateos, MV, Moreau, P, Oliynyk, H, Peddagali, V, Pour, L, Pylypenko, H, Quach, H, Radinoff, A, Reece, D, Richardson, PG, Robak, P, Saint-Martin, J-R, Salogub, G, Shacham, S, Shah, J, Simonova, M, Sinha, DK, Spicka, I, St Goranova-Marinova, V, Stevens, DA, Usenko, G, Venner, CP, Wallington-Beddoe, C, White, D   +57 more
core   +1 more source

Loncastuximab Tesirine in a Frail, Heavily Pretreated Patient With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Case Report

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Loncastuximab tesirine may offer a feasible, well‐tolerated option for frail, heavily pretreated patients with relapsed/refractory DLBCL and poor performance status when intensive therapies are unsuitable, achieving durable remission with manageable fluid retention through careful monitoring, spironolactone‐based treatment, and dose ...
Reyad Dada, Refaei Belal Ibrahim
wiley   +1 more source

Selinexor in combination with dexamethasone with or without bortezomib in heavily pretreated multiple myeloma: A case series

eJHaem
This report describes the characteristics and outcomes of 18 heavily pretreated patients with multiple myeloma (MM) who were subsequently treated with selinexor.
Nini Aung, Margaret Bowers, Gillian Brearton, Andrew Charlton, Joanne Craig, Jonathan Cullis, Ray Dang, David Donaldson, Mary Drake, Rachel Hall, Elizabeth Parkins, Jane Tighe, Ceri Bygrave, Oonagh Sheehy   +13 more
doaj   +1 more source

Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD‐1 Inhibitor and Niraparib in GErm‐Line‐mutAted Metastatic Breast Cancer

MedComm, Volume 7, Issue 4, April 2026.
This phase II trial evaluated the efficacy and safety of niraparib combined with HX008 in metastatic breast cancer (MBC) patients with germline DNA damage response (DDR) gene mutations. This chemotherapy‐free regimen demonstrates promising efficacy and a tolerable safety profile in MBC patients with germline DDR mutations, providing a novel therapeutic
Jian Zhang, Yiqun Du, Yanchun Meng, Yizi Jin, Mingxi Lin, Xuchen Shao, Xiaojun Liu, Yuxin Mu, Yun Liu, Zhen Hu   +9 more
wiley   +1 more source

Clinical Applications of Phosphoproteomics: Illuminating Cancer Signaling and Enabling Rational Therapeutic Strategies

Cancer Science, Volume 117, Issue 4, Page 885-895, April 2026.
Mass spectrometry‐based phosphoproteomics for mechanistic dissection of cancer signaling pathways and uncovering therapeutic vulnerabilities. ABSTRACT Protein phosphorylation is a central post‐translational modification regulating cellular signaling, frequently dysregulated in cancer.
Hirokazu Shoji, Narikazu Boku, Jun Adachi   +2 more
wiley   +1 more source

Resultados en salud en el tratamiento del mieloma múltiple [PDF]

, 2019
Introducción: El mieloma múltiple es una neoplasia caracterizada por la proliferación incontrolada de células plasmáticas. Es necesario realizar un análisis retrospectivo para evaluar la efectividad de los tratamientos administrados ...
Aguado Paredes, Alicia
core